79
Participants
Start Date
February 25, 2014
Primary Completion Date
January 23, 2015
Study Completion Date
October 26, 2016
E/C/F/TAF
E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Whitman Walker Health, Washington D.C.
AIDS Research and Treatment Center of the Treasure Coast, Vero Beach
AIDS Health Foundation/WPA, Miami Beach
Gary J Richmond M.D.,P.A., Fort Lauderdale
Triple O Research Institute PA, West Palm Beach
Barry M. Rodwick MD, Clearwater
Midway Immunology and Research Center, Ft. Pierce
Be Well Medical Center PC, Berkley
Southampton Healthcare, Inc., St Louis
KC Care Clinic, Kansas City
North Texas Infectious Diseases Consultants, Dallas
Therapeutic Concepts, Houston
Gordon E. Crofoot MD PA, Houston
Central Texas Clinical Research, Austin
Spectrum Medical Group, Phoenix
Southwest CARE Center, Santa Fe
Peter J. Ruane MD, Inc., Los Angeles
Anthony Mills MD, Inc, Los Angeles
AHF Research Center, Beverly Hills
Peter Shalit MD, Seattle
Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku
St. Hope Foundation, Bellaire
University Health Network/Toronto General Hospital, Toronto
Maple Leaf Research/Maple Leaf Medical Clinic, Toronto
Lead Sponsor
Gilead Sciences
INDUSTRY